Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ofatumumab + Chlorambucil vs Chlorambucil in Untreated CLL
NCT00748189Phase 3Terminated
- Sponsor
- Novartis
- Start
- Dec 2008
- Primary completion
- Mar 2013
- Modality
- Monoclonal Antibodies
- Countries
- 17
01
Overview
A Phase 3 trial of ofatumumab in chronic lymphocytic leukemia (CLL), sponsored by Novartis. Started Dec 2008; status: terminated.
02
Drugs
ofatumumab
03
Conditions
chronic lymphocytic leukemia (CLL)
Beyond the preview
Go deeper on NCT00748189.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00748189.